In the global pharmaceutical industry, there were 66 private equity deals announced in Q4 2023, worth a total value of $4.1bn, according to GlobalData’s Deals Database. The $1.2bn management buy-out (mbo) Sogo Medical Group by CVC Asia V was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity decreased by 34% in Q4 2023 compared with the previous quarter’s total of $6.2bn and fell by 28% as compared to Q4 2022. Related deal volume increased by 10% in Q4 2023 versus the previous quarter and was 31% lower than in Q4 2022.
Notably, foreign direct investments (fdi)-related deals accounted for a 33% share of the global pharmaceutical industry’s private equity deal activity in Q4 2023, up 16% over the previous quarter.
The top-ranked financial advisors supporting these private equity deals in Q4 2023 were Houlihan Lokey; Rothschild & Co; PricewaterhouseCoopers International with 9, 8, 7 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Q4 2023 were Kirkland & Ellis; Goodwin Procter; McDermott Will & Emery with 14, 9, 8 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.